ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
편두통 치료 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 2029년에는 CAGR 10.9%로 52억 1,000만 달러로 성장할 것입니다. 예측 기간의 성장은 인식 개선 및 교육, 단클론항체의 출현, 소아 편두통에 대한 관심 증가, 비약리학적 개입의 확대, 편두통 연구를 위한 세계 이니셔티브에 기인합니다. 예측 기간의 주요 동향으로는 치료 접근법의 발전, 웨어러블 기기 및 디지털 치료, 원격의료 및 원격진료, 환자 중심 치료 모델, 제네릭 의약품 시장 성장, 경구용 CGRP 억제제 등이 있습니다.
향후 5년간 10.9%의 성장률 전망은 지난번 예측보다 0.3% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역 마찰은 캐나다와 영국에서 개발된 경두개 자기자극(TMS) 장치와 스마트립탄 비강 자가주사기의 가격을 급등시켜 환자의 고통을 연장시키고 응급의료비를 상승시킴으로써 미국의 첨단 편두통 치료법 채택을 방해할 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.
스크린에 대한 장시간 노출 증가는 편두통 치료 시장의 성장을 촉진할 것으로 예상됩니다. 화면 노출이란 개인이 스마트폰, 태블릿, 컴퓨터, TV 등 전자 스크린에 노출되는 시간을 말합니다. 스크린 노출의 장기화 요인으로는 원격 근무의 증가, 온라인 교육, 디지털 엔터테인먼트, 사회적 교류의 기술 의존도 증가 등을 꼽을 수 있습니다. 편두통 치료는 장시간 스크린 사용으로 유발되거나 악화되는 증상을 치료하는 것으로, 약물 치료, 생활습관 개선, 인체공학적 부담 경감 및 발작 예방을 목적으로 합니다. 예를 들어, 2024년 5월 영국 의회 내 보건 기관인 하원 위원회는 2021년 어린이들의 스크린 사용 시간이 52% 급증했으며, 어린이와 청소년의 25% 가까이가 스마트폰 사용 패턴이 행동 중독을 보입니다고 보고했습니다. 그 결과, 스크린에 대한 장시간 노출이 편두통 치료 시장의 성장을 주도하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 편두통 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 편두통 치료 시장 : 성장률 분석
세계의 편두통 치료 시장 실적 : 규모와 성장, 2019-2024
세계의 편두통 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 편두통 치료 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 편두통 치료 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
반복성
조짐 편두통
만성
기타 유형
세계의 편두통 치료 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
급성기 치료 또는 예방 치료
예방적 치료
비약물요법과 디바이스
세계의 편두통 치료 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
클리닉
재택 케어
기타 최종사용자
세계의 편두통 치료 시장 : 하위 세분화 반복성, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
빈번한 반복성 편두통
희귀한 반복성 편두통
세계의 편두통 치료 시장 : 하위 세분화 조짐 편두통, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
시각적 조짐
감각적 조짐
스피치 또는 언어 조짐
세계의 편두통 치료 시장 : 하위 세분화 만성, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
무조짐 만성 편두통
무조짐 만성 편두통
세계의 편두통 치료 시장 : 하위 세분화 기타 유형, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
편마비성 편두통
망막 편두통
생리성 편두통
기타 특정 유형
제7장 지역별·국가별 분석
세계의 편두통 치료 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 편두통 치료 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
편두통 치료 시장 : 경쟁 구도
편두통 치료 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Bayer AG
Allergan PLC
Abbott Laboratories
Allodynic Therapeutics LLC
AOBiome LLC
AstraZeneca PLC
Bausch Health Companies Inc.
Boehringer Ingelheim International GmbH
Dr. Reddy's Laboratories Limited
Impel Pharmaceuticals Inc.
AbbVie Inc.
Alder BioPharmaceuticals Inc.
Astellas Pharma Inc.
Biohaven Pharmaceutical Holding Company Ltd.
Bristol-Myers Squibb Company
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
편두통 치료 시장 2029 : 새로운 기회를 제공하는 국가
편두통 치료 시장 2029 : 새로운 기회를 제공하는 부문
편두통 치료 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
KSM
영문 목차
영문목차
Migraines, a neurological condition, are characterized by severe headaches typically felt on one side of the brain. These pulsating headaches are the primary symptom of this condition. Migraine treatment aims to alleviate these intense and often debilitating headaches by targeting the brain's pain pathways. By effectively blocking these pathways, the treatment can halt future migraine attacks and alleviate associated symptoms.
Different types of migraine treatments cater to varying migraine presentations. Episodic migraine treatment addresses instances where individuals experience headaches for 0-14 days per month. This form of treatment encompasses various acute options tailored specifically for episodic migraines. Available treatments include acute/abortive methods, preventive/prophylactic approaches, as well as non-pharmacological therapies and devices. These treatments find applications across diverse settings, including hospitals, clinics, homecare, and other end-user environments.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The migraine treatment market research report is one of a series of new reports from The Business Research Company that provides migraine treatment market statistics, including migraine treatment industry global market size, regional shares, competitors with a migraine treatment market share, detailed migraine treatment market segments, market trends and opportunities, and any further data you may need to thrive in the migraine treatment industry. This migraine treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The migraine treatment market size has grown strongly in recent years. It will grow from $3.18 billion in 2024 to $3.45 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased prevalence of migraines, increased healthcare expenditure, improved formulations of existing drugs, expansion of clinical research, development of novel therapies.
The migraine treatment market size is expected to see rapid growth in the next few years. It will grow to $5.21 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to growing awareness and education, emergence of monoclonal antibodies, increasing focus on pediatric migraines, expansion of non-pharmacological interventions, global initiatives for migraine research. Major trends in the forecast period include advancements in therapeutic approaches, wearable devices and digital therapeutics, telemedicine and remote consultations, patient-centric care models, generic drug market growth, oral CGRP inhibitors.
The forecast of 10.9% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of advanced migraine therapies by inflating prices of transcranial magnetic stimulation (TMS) devices and nasal sumatriptan autoinjectors developed in Canada and the UK, resulting in prolonged patient suffering and higher emergency care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increase in prolonged screen exposure is anticipated to drive the growth of the migraine treatment market. Screen exposure refers to the duration individuals spend engaging with electronic screens, including those on smartphones, tablets, computers, and televisions. Factors contributing to prolonged screen exposure include the rise in remote work, online education, digital entertainment, and a greater reliance on technology for social interactions. Migraine treatments address symptoms that are triggered or exacerbated by extended screen time, encompassing medications, lifestyle changes, and ergonomic practices aimed at reducing strain and preventing attacks. For example, in May 2024, the House of Commons Committee, a health agency within the UK Parliament, reported that children's screen time surged by 52% in 2021, with nearly 25% of children and young people displaying smartphone usage patterns indicative of behavioral addiction. As a result, prolonged screen exposure is driving the growth of the migraine treatment market.
The escalating number of clinical trials stands as a catalyst for the migraine treatment market's expansion. These trials, involving human participants, aim to evaluate the safety and effectiveness of new medical interventions for migraines. They offer insights into personalized treatment strategies and potentially more efficient therapies. As per Xtalks in May 2023, there were 452,604 registered clinical studies on ClinicalTrials.gov, with 64,838 actively seeking participants-a significant increase from 2021's 365,000 registered trials. This surge in clinical trials actively contributes to the burgeoning migraine treatment market.
Product innovations are a prominent trend gaining traction in the migraine treatment market. Leading companies in the sector are introducing novel solutions, such as liquid formulations, to maintain their competitive edge. For example, in January 2022, BioDelivery Sciences International (BDSI), a US-based pharmaceutical firm, launched Elyxyb (celecoxib oral solution), designed for the acute treatment of migraines in adults, regardless of whether they experience aura. This liquid formulation facilitates rapid absorption in the small intestine, resulting in quicker relief compared to conventional tablets. This innovation is particularly advantageous for migraine sufferers who experience nausea or vomiting, as it eliminates the waiting time for a pill to dissolve. As the first and only FDA-approved ready-to-use oral solution for migraines, Elyxyb offers a more tolerable and efficient treatment option for managing the sudden, intense pain associated with migraines.
Major players in the migraine treatment market prioritize product approvals, such as the zavzpret (zavegepant) migraine nasal spray, to bolster market revenues. Zavzpret, a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray, targets the acute management of adult migraines. Notably, Pfizer Inc. received FDA approval for zavzpret (zavegepant) in March 2023. This nasal spray offers immediate relief for adult migraine attacks, aiming to provide pain relief with a single spray. The FDA's endorsement marks a significant milestone for migraine sufferers seeking alternatives to oral medications for prompt pain relief.
In May 2022, Pfizer Inc., a prominent biopharmaceutical company based in the US, successfully completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for an estimated $11.6 billion. This strategic acquisition positions Pfizer to further its commitment in providing effective treatments for individuals worldwide afflicted by migraines. Biohaven Pharmaceutical Holding Company Ltd., also based in the US, possesses a diverse product portfolio focused on addressing neuropsychiatric diseases and neurological disorders.
Major companies operating in the migraine treatment market are Pfizer Inc., Eli Lilly and Company, Amgen Inc., GlaxoSmithKline PLC, Novartis AG, Bayer AG, Allergan PLC, Abbott Laboratories, Allodynic Therapeutics LLC, AOBiome LLC, AstraZeneca PLC, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Limited, Impel Pharmaceuticals Inc., AbbVie Inc., Alder BioPharmaceuticals Inc., Astellas Pharma Inc., Biohaven Pharmaceutical Holding Company Ltd., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Endo International PLC, Impax Laboratories Inc., Johnson & Johnson Inc., Lannett Company Inc., Lupin Limited, Merck & Co. Inc., Mylan N.V.
North America was the largest region in the migraine treatment market in 2024. The regions covered in the migraine treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the migraine treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The migraine treatment market includes revenues earned by entities by providing branded and generic migraine treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Migraine Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on migraine treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for migraine treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The migraine treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Types: Episodic; Migraine With Aura; Chronic; Other Types
2) By Treatment: Acute Or Abortive Treatment; Preventive Or prophylactic Treatment; Non-Pharmacological Therapies And Devices
3) By End-User: Hospitals; Clinics; Homecare; Other End-users
Subsegments:
1) By Episodic: Frequent Episodic Migraine; Infrequent Episodic Migraine
2) By Migraine With Aura: Visual Aura; Sensory Aura; Speech Or Language Aura
3) By Chronic: Chronic Migraine Without Aura; Chronic Migraine With Aura
4) By Other Types: Hemiplegic Migraine; Retinal Migraine; Menstrual Migraine; Other Specific Types
Companies Mentioned: Pfizer Inc.; Eli Lilly and Company; Amgen Inc.; GlaxoSmithKline PLC; Novartis AG; Bayer AG; Allergan PLC; Abbott Laboratories; Allodynic Therapeutics LLC; AOBiome LLC; AstraZeneca PLC; Bausch Health Companies Inc.; Boehringer Ingelheim International GmbH; Dr. Reddy's Laboratories Limited; Impel Pharmaceuticals Inc.; AbbVie Inc.; Alder BioPharmaceuticals Inc.; Astellas Pharma Inc.; Biohaven Pharmaceutical Holding Company Ltd.; Bristol-Myers Squibb Company; Daiichi Sankyo Company Limited; Eisai Co. Ltd.; Endo International PLC; Impax Laboratories Inc.; Johnson & Johnson Inc.; Lannett Company Inc.; Lupin Limited; Merck & Co. Inc.; Mylan N.V.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Migraine Treatment Market Characteristics
3. Migraine Treatment Market Trends And Strategies
4. Migraine Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Migraine Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Migraine Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Migraine Treatment Market Growth Rate Analysis
5.4. Global Migraine Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Migraine Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Migraine Treatment Total Addressable Market (TAM)
6. Migraine Treatment Market Segmentation
6.1. Global Migraine Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Episodic
Migraine With Aura
Chronic
Other Types
6.2. Global Migraine Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Or Abortive Treatment
Preventive Or Prophylactic Treatment
Non-Pharmacological Therapies And Devices
6.3. Global Migraine Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Homecare
Other End-users
6.4. Global Migraine Treatment Market, Sub-Segmentation Of Episodic, By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Frequent Episodic Migraine
Infrequent Episodic Migraine
6.5. Global Migraine Treatment Market, Sub-Segmentation Of Migraine With Aura, By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Visual Aura
Sensory Aura
Speech Or Language Aura
6.6. Global Migraine Treatment Market, Sub-Segmentation Of Chronic, By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chronic Migraine Without Aura
Chronic Migraine With Aura
6.7. Global Migraine Treatment Market, Sub-Segmentation Of Other Types, By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hemiplegic Migraine
Retinal Migraine
Menstrual Migraine
Other Specific Types
7. Migraine Treatment Market Regional And Country Analysis
7.1. Global Migraine Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Migraine Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
